[
  {
    "ts": "2025-12-09T10:27:00+00:00",
    "headline": "Strategic Pharma Collaborations Propel RCC Market Growth",
    "summary": "The global advanced renal cell carcinoma (RCC) market is experiencing rapid growth driven by innovative treatment approaches, rising disease awareness, and an expanding patient base. Key factors include the adoption of targeted therapies and immunotherapies, personalized medicine, and strategic collaborations among industry leaders such as Pfizer, Merck & Co., and AstraZeneca.Dublin, Dec. 09, 2025 (GLOBE NEWSWIRE) -- The \"Advanced Renal Cell Carcinoma (RCC) Market - A Global and Regional Analysi",
    "url": "https://finance.yahoo.com/news/strategic-pharma-collaborations-propel-rcc-102700645.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "a91df546-a5ff-36e2-878b-8d7e920eac4f",
      "content": {
        "id": "a91df546-a5ff-36e2-878b-8d7e920eac4f",
        "contentType": "STORY",
        "title": "Strategic Pharma Collaborations Propel RCC Market Growth",
        "description": "",
        "summary": "The global advanced renal cell carcinoma (RCC) market is experiencing rapid growth driven by innovative treatment approaches, rising disease awareness, and an expanding patient base. Key factors include the adoption of targeted therapies and immunotherapies, personalized medicine, and strategic collaborations among industry leaders such as Pfizer, Merck & Co., and AstraZeneca.Dublin, Dec. 09, 2025 (GLOBE NEWSWIRE) -- The \"Advanced Renal Cell Carcinoma (RCC) Market - A Global and Regional Analysi",
        "pubDate": "2025-12-09T10:27:00Z",
        "displayTime": "2025-12-09T10:27:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/strategic-pharma-collaborations-propel-rcc-102700645.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/strategic-pharma-collaborations-propel-rcc-102700645.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "AZN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-09T11:55:00+00:00",
    "headline": "Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement",
    "summary": "Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, Chongqing Yao Pharmaceutical Company, Limited. (\"Yao Pharma\"), Shanghai Fosun Pharmaceutical Industrial Development Company Limited, and Pfizer Inc. (NYSE: PFE) have entered into an exclusive collaboration and license agreement. Under this agreement, Yao Pharma grants Pfizer an exclusive worldwide license for the development, use, manufacturing, and commercialization of oral small-molecule glucagon-like peptide-1 rece",
    "url": "https://finance.yahoo.com/news/fosun-pharmas-subsidiary-yao-pharma-115500092.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "2feac2e4-ea41-3769-9bf8-8b3d8686b443",
      "content": {
        "id": "2feac2e4-ea41-3769-9bf8-8b3d8686b443",
        "contentType": "STORY",
        "title": "Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement",
        "description": "",
        "summary": "Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, Chongqing Yao Pharmaceutical Company, Limited. (\"Yao Pharma\"), Shanghai Fosun Pharmaceutical Industrial Development Company Limited, and Pfizer Inc. (NYSE: PFE) have entered into an exclusive collaboration and license agreement. Under this agreement, Yao Pharma grants Pfizer an exclusive worldwide license for the development, use, manufacturing, and commercialization of oral small-molecule glucagon-like peptide-1 rece",
        "pubDate": "2025-12-09T11:55:00Z",
        "displayTime": "2025-12-09T11:55:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/ab9d596447b220ac4e9523a3e157a944",
          "originalWidth": 16,
          "originalHeight": 16,
          "caption": "Cision",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rM96VtUZkIca69kjD3HKng--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/ab9d596447b220ac4e9523a3e157a944.cf.webp",
              "width": 16,
              "height": 16,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2S9PfH8htvNBXaNuQzh3ag--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/ab9d596447b220ac4e9523a3e157a944.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/fosun-pharmas-subsidiary-yao-pharma-115500092.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/fosun-pharmas-subsidiary-yao-pharma-115500092.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "SFOSF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-09T11:30:00+00:00",
    "headline": "Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma",
    "summary": "NEW YORK, December 09, 2025--Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Limited (02196.HK and 600106.SH), a leading innovation-driven global healthcare company, for the development, manufacturing and commercialization of YP05002, a small molecule glucagon-like peptide 1 (GLP-1) receptor agonist currently in Phase 1 development for chronic weight mana",
    "url": "https://finance.yahoo.com/news/pfizer-enters-exclusive-collaboration-license-113000303.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "27560721-10ed-3286-9723-a65bc02b14ef",
      "content": {
        "id": "27560721-10ed-3286-9723-a65bc02b14ef",
        "contentType": "STORY",
        "title": "Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma",
        "description": "",
        "summary": "NEW YORK, December 09, 2025--Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Limited (02196.HK and 600106.SH), a leading innovation-driven global healthcare company, for the development, manufacturing and commercialization of YP05002, a small molecule glucagon-like peptide 1 (GLP-1) receptor agonist currently in Phase 1 development for chronic weight mana",
        "pubDate": "2025-12-09T11:30:00Z",
        "displayTime": "2025-12-09T11:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/09ea9779b53ba4a48ad58ea64e455ec5",
          "originalWidth": 480,
          "originalHeight": 212,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/29uW19vvGSMGQt7U0ERcsw--~B/aD0yMTI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/09ea9779b53ba4a48ad58ea64e455ec5.cf.webp",
              "width": 480,
              "height": 212,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3_kJYtmIghcH5VzGhidhVQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/09ea9779b53ba4a48ad58ea64e455ec5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-enters-exclusive-collaboration-license-113000303.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-enters-exclusive-collaboration-license-113000303.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-09T14:26:13+00:00",
    "headline": "Pfizer gains another obesity asset with $2bn deal for YaoPharma’s GLP-1RA",
    "summary": "This comes just under a month after Pfizer finalised a deal to acquire Metsera following a bidding war with Novo Nordisk.",
    "url": "https://www.pharmaceutical-technology.com/news/pfizer-gains-another-obesity-asset-with-2bn-deal-for-yaopharmas-glp-1ra/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "5805f0ba-bf0a-3d66-a0fd-5f5b76ee4331",
      "content": {
        "id": "5805f0ba-bf0a-3d66-a0fd-5f5b76ee4331",
        "contentType": "STORY",
        "title": "Pfizer gains another obesity asset with $2bn deal for YaoPharma’s GLP-1RA",
        "description": "",
        "summary": "This comes just under a month after Pfizer finalised a deal to acquire Metsera following a bidding war with Novo Nordisk.",
        "pubDate": "2025-12-09T14:26:13Z",
        "displayTime": "2025-12-09T14:26:13Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/f444263393eebe90d809cdc894845c85",
          "originalWidth": 1000,
          "originalHeight": 662,
          "caption": "Pfizer will pay $150m upfront with more than $1.9bn available for YaoPharma",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/UtHH0Gbg00SpSrCluCwAZQ--~B/aD02NjI7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/f444263393eebe90d809cdc894845c85.cf.webp",
              "width": 1000,
              "height": 662,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hQYPyveCagSDA9cSqmHMJg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/f444263393eebe90d809cdc894845c85.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/pfizer-gains-another-obesity-asset-with-2bn-deal-for-yaopharmas-glp-1ra/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-gains-another-obesity-asset-142613402.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-09T09:22:00+00:00",
    "headline": "CRDF: Initiating Coverage – Combination Therapy Elicits Superior Response",
    "summary": "By John Vandermosten, CFA NASDAQ:CRDF READ THE FULL CRDF RESEARCH REPORT We are initiating coverage of Cardiff Oncology, Inc. (NASDAQ:CRDF) with a valuation of $8.50 per share. This value is based on our estimates for successful development and commercialization of onvansertib for first line treatment of patients with metastatic colorectal cancer (mCRC). Onvansertib is a Polo-Like kinase 1 (PLK1)",
    "url": "https://finance.yahoo.com/news/crdf-initiating-coverage-combination-therapy-092200278.html",
    "source": "Zacks Small Cap Research",
    "provider": "yfinance",
    "raw": {
      "id": "261b91fd-701c-3e97-81dc-60541203181c",
      "content": {
        "id": "261b91fd-701c-3e97-81dc-60541203181c",
        "contentType": "STORY",
        "title": "CRDF: Initiating Coverage – Combination Therapy Elicits Superior Response",
        "description": "",
        "summary": "By John Vandermosten, CFA NASDAQ:CRDF READ THE FULL CRDF RESEARCH REPORT We are initiating coverage of Cardiff Oncology, Inc. (NASDAQ:CRDF) with a valuation of $8.50 per share. This value is based on our estimates for successful development and commercialization of onvansertib for first line treatment of patients with metastatic colorectal cancer (mCRC). Onvansertib is a Polo-Like kinase 1 (PLK1)",
        "pubDate": "2025-12-09T09:22:00Z",
        "displayTime": "2025-12-09T09:22:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/scr.zacks.com/3ddb6c0adff87ff9f2fd63f7eb605860",
          "originalWidth": 1355,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EkRbZxxbL9UhexIGqrhEpA--~B/aD00MDA7dz0xMzU1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/3ddb6c0adff87ff9f2fd63f7eb605860.cf.webp",
              "width": 1355,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SNb1XjtlEYBw31IJCdRAEQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/scr.zacks.com/3ddb6c0adff87ff9f2fd63f7eb605860.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks Small Cap Research",
          "url": "http://scr.zacks.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/crdf-initiating-coverage-combination-therapy-092200278.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/crdf-initiating-coverage-combination-therapy-092200278.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CRDF"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]